Wockhardt Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Wockhardt Ltd is up for a third straight session today. The stock is quoting at Rs 1513.7, up 3.27% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.37% on the day, quoting at 26081.2. The Sensex is at 84749.13, down 0.37%. Wockhardt Ltd has gained around 15.08% in last one month.

Meanwhile, Nifty Pharma index of which Wockhardt Ltd is a constituent, has gained around 2.29% in last one month and is currently quoting at 23126.85, up 0.13% on the day. The volume in the stock stood at 6.09 lakh shares today, compared to the daily average of 9.18 lakh shares in last one month.

The PE of the stock is 168.77 based on TTM earnings ending September 25.

Powered by Capital Market - Live News

Wockhardt has successfully filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic, WCK 5222, on 5 January 2026.

The EMA is the regulatory authority responsible for the scientific evaluation, of new medicines across the 27 European Union (EU) Member States and three European Economic Area (EEA) countries?Iceland, Liechtenstein, and Norway?covering a total of 30 countries.

Earlier, the EMA had informed Wockhardt that WCK 5222, a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g), is eligible for Accelerated Assessment. This pathway allows for an abridged review timeline, reflecting the unmet medical need addressed by the product. The New Drug Application (NDA) on WCK 5222 is already under fast-track review by the US FDA.

Based on the comprehensive clinical and regulatory data included in the application, Wockhardt expects WCK 5222 approval for treatment of resistant Gram negative infections across all countries under the EMA's jurisdiction. The priority review status granted to WCK 5222 underscores the global urgency to make effective treatment options available for patients suffering from life-threatening multi-drug resistant infections.

Notably, WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation.

Powered by Capital Market - Live News

The European Medicines Agency (EMA) has informed Wockhardt that WCK 5222 (combination of Zidebactam 1g + Cefepime 2g) is eligible for Accelerated Assessment, following a pre-submission meeting with the EMA review team.

The Accelerated Assessment designation reflects EMA??s view that WCK 5222 has the potential to address an unmet medical need by providing an effective therapeutic option for the treatment of following serious and life-threatening infections, particularly those caused by multi-drug-resistant (MDR) and extremely drug resistant (XDR) Gram negative pathogens.

• Complicated urinary tract infections (cUTI), including pyelonephritis ?h
• Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) ?h
• Complicated intra-abdominal infections (cIAI) ?h
• Treatment of patients with bacteraemia occurring in association with, or suspected to be associated with, cUTI/acute pyelonephritis, HAP/VAP, or cIAI ?h
• Treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options

If approved, the proposed breadth of indications would support the use of WCK 5222 across a wide range of serious infections and contribute to addressing the growing public health challenge of antimicrobial resistance. WCK 5222 represents the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation, reflecting the advancement of an India-initiated global antimicrobial innovation efforts.

Powered by Capital Market - Live News

Wockhardt Ltd is up for a fifth straight session today. The stock is quoting at Rs 1436, up 1.76% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.6% on the day, quoting at 26121.85. The Sensex is at 85355.3, up 0.5%. Wockhardt Ltd has gained around 11.09% in last one month.

Meanwhile, Nifty Pharma index of which Wockhardt Ltd is a constituent, has gained around 1.81% in last one month and is currently quoting at 22751.25, up 0.65% on the day. The volume in the stock stood at 3.94 lakh shares today, compared to the daily average of 25.21 lakh shares in last one month.

The PE of the stock is 162.51 based on TTM earnings ending September 25.

Powered by Capital Market - Live News